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The hst-l gene, which is implicated in mammalian embryonic development and morphological transformation of NIH3T3 cells, is expressed in 
undifferentiated F9 cells, but not in differentiated F9 and other well-differentiated cells, such as PYS-2, NIH3T3 and HeLa cells. An octamer element 
present in the 3’ untranslated region acts as an enhancer. Although Oct3 is down-regulated when F9 cells are differentiated, transient expression of 
Oct3 did not enhance the hst-1 promoter activity in HeLa, NIH3T3 or PYS-2 cells. Thus, the role of Oct3 on h-1 expression remains elusive, and 
an additional transcription factor which interacts may regulate hst-I transcription in association with Gctl, Gct3 or both. 
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1. Introduction 
The M-1 gene (K-~G~/FGF~ is a transfo~ng gene 
initially identified through transfection of high molecular 
weight DNA from various sources into NIH3T3 cells 
[l-3]. Hstl protein is homologous to members of the 
fibroblast growth factor (FGF) family [4,5]. Among 7 
members of this group&t-21FGF3 [6-81, FGFS [9], and 
~~f-Z/~GF6 [l&12], in addition to hst-i [13-163 are exclu- 
sively expressed in embryo and embryonal carcinoma 
cells; acidic and basic FGFs are expressed both in embry- 
onal carcinoma cells and in differentiated cells [15]; and 
KGF is expressed in keratinocytes [17]. During the em- 
bryonic development of mouse, M-1 is expressed as 
early as the late blastocyst stage and its expression be- 
comes restricted to the tail bud which is the primary 
source of the mesoderm [18]. The hst-Z gene is also ex- 
pressed transiently in the branchial arc units, the somitic 
myotome, the limb and tooth buds, and thus may have 
multiple roles in embryonal development [18]. Transcrip- 
tion of M-1 is turned off when F9 cells differentiate into 
endoderm-like cells [ 13,141. The transcription is depend- 
ent on the non-coding region of the third exon [19-221. 
Octamer-like [23] and engrailed (En)-like [24] sequences 
present in the third exon have been considered as the 
candidates. Shoorlemmer and Kruijer [22] reported the 
involvement of the octamer motif by deletion experi- 
ments. 
Oct3, which is expressed in undifferentiated embry- 
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onal carcinoma cells and is down-regulated after differ- 
entiation, may regulate hst-I expression. In fact Ma et al. 
[21] reported that transfection of an act3 expression 
plasmid into PYS-2 cells enhanced hst-2 promoter activ- 
ity. However, the proof that the /&-I gene is the target 
for Oct3 has not yet been unambiguously established. 
Here we report the mutational analysis of the 3’ enhancer 
region of the human hst-f gene and the effect of the 
transfected act-3 expression plasmid on the hst-l pro- 
moter in various differentiated cells. Our results indicate 
the involvement of an additional transcription factor 
which is expressed differentially in F9 cells and which 
interacts with either Octl, Oct3 or both. 
2. Materials and methods 
2.1. Plasmi& and synthetic oligonucleotides 
A human hst-1 clone, BM5, which was isolated from an NIH3T3 
transformant [Z], was used to construct CAT plasmids. The sequence 
was numbered such that the major transcriptional initiation site was + 1 
which corresponds to 2,279 of the human genomic hst-l reported by 
Yoshida et al. 1251. To a unique Hind111 site of pSVOOCAT [26], the 
following DNA fragments derived from BMS were inserted using an 
Hind111 linker: MA, a Mbol-ApaI fragment spanning from 1,295 to 
105; BA, a BsrI-ApaI fragment spanning from -282 to 105; RA, a 
RmaI-&a1 fragment spanning from -172 to 105; -64/92, a DNA 
fragment spanning from -64 to 92 generated by polymerase chain 
reaction (PCR) [27J between a sense (S~~~gctt~A~GAG- 
TAGGA3’) and an antisense (SagtaagcttCTCTACCCCGGCTGC- 
AT3’) primer. The BamHI site of pSVGGCAT was converted to an 
XbaI site where the following DNA fragments were inserted. E2S, a 
BstE2-SalI fragment spanning from 3,318 to 3,881; 51, a DNA frag- 
ment spanning from 3,193 to 3,392 generated byPCR between a sense 
(SatatctAGATAGCGTCGGTGCGTCC3’) and an antisense (S’ggat- 
ctagaCM’CCACGGTTGCTTCA3~ primer; 52, a DNA fragment 
spanning from 3,376 to 3,517 generated by PCR between a sense 
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(S’aggtctagaTGAAGCAACCGTGGAAG3’) and an antisense (Scag- 
tctagaGAAACATTCGGAGCATT3’) primer; 53, a DNA fragment 
spanning from 3,548 to 3,717 generated by PCR between a sense 
(S’gtgtctagaTCTGAACTGTCTCCCGA3’) and an antisense (5’ccgtct- 
agaGCAAGTGTCTTCTTTCT3’) primer; and 52+53, a DNA frag- 
ment spanning from 3,376 to 3,717 generated by PCR between a sense 
(5’aggtctagaTGAAGCAACCGTGGAAG3’) and an antisense (Sccg- 
tctagaGCAAGTGTCTTCTTTCT3’) primer. 53M1,53M2 and 53M3 
were mutant 53 fragments produced by site-directed mutagensis using 
S’GTTCGAATGCcccTCATCGACTT3’ and S’TCATCGACTTccc- 
ATACTATTCT3’ oligonucleotides for mutating octamer/En-like se- 
quences (see Fig. 1C). These mutant 53 fragments were cloned into 
pUC18, sequenced, cut with XbaI and inserted into the XbaI site of 
CAT plasmids. A 39mer dsDNA fragment spanning 3,650-3,688 (E39) 
was produced by annealing two synthetic oligonucleotides. A 22 bp 
ds-oligonucleotide, the sense strand of which was STGTCGAATGC- 
AAATCACTAGAA3’, containing a consensus octamer sequence but 
not an En-like sequence, was synthesized. A cytomegalovirus- 
promoter(CMV) driven act-3 expression plasmid was supplied by Dr. 
H. Hamada [28]. 
2.2. Cell culture and CAT assay 
F9 cells were cultured in gelatin-coated ishes and HeLa, NIH3T3 
and PYS-2 cells were cultured in conventional plastic dishes 100 mm 
in diameter. For transfection with various plasmids, a total of 30 or 
31 pug DNA (by adding pUCl8 DNA) was co-precipitated with calcium 
phosphate as previously described [20]. Cells were exposed to calcium 
precipitates for 24 h and harvested 24 h thereafter. The CAT assay was 
performed as described previously [20] and, in several experiments, the 
activity was corrected for transfection efficiency by expression of co- 
transfected pCHll0 [29] or pRSV-LacZ plasmid. The latter was con- 
structed by insertion of a RSV-driven IacZ gene into pBluescript KS 
(T.K., unpublished). For differentiation of F9, 1 mg/ml dibutyryl cyclic 
AMP and 10e6 M retinoic acid were added at day -2 of the transfection. 
2.3. Band shift assay 
Nuclear extracts were prepared as described by Schreiber et al. [30], 
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adding the following protease inhibitors; 1 ,uM PMSF, 1 @ml 
leupeptin, 1 @ml pepstatin A and 0.3 pug/ml antipain. Probes were 5 
end-labeled with [y-‘*P]ATP. Binding reactions were carried out in 20 
~1 solutions containing 20 mM Tris-HCl (pH 7.8),50 mM NaCl, 0.5 
mM EDTA, 0.5 mM DTT and 5% glycerol [31]. 10,000 cpm of probe 
(containing 0.1-0.5 ng) and 5 pug of nuclear extract were incubated at 
room temperature for 10 min. To reduce the non- specific binding of 
nuclear proteins to the probe, 2 or 4 pg of poly(dI-dC) were included 
in the mixture. 5 ~1 fractions of the reaction mixtures were resolved by 
4% polyacrylamide gel electrophoresis [32]. For competitive band shift 
assays, a 200-fold molar excess of unlabelled DNA fragments or equiv- 
alent amounts of pUC18 were used. 
3. Results 
As E2S (3,318/3,881) showed enhancer activity when 
inserted 3’ to MA-00-CAT [20], we tested the enhancer 
activity of the PCR-generated fragments, 51, 52, 53 and 
52 + 53. Fragments 53 and 52 + 53 enhanced the hst-1 
promoter almost 10 fold (Fig. 2A and data not shown). 
In 53, an octamer sequence, ATGCAAAT (3,656/ 
3,663),and an En-like sequence, ACTTAAAATA (3,669/ 
3,678) are present, although the octamer sequence in the 
mouse was ATGCtAAT. We next tried to discriminate 
between the enhancer activity of these two motifs. Three 
mutant fragments, 53M1, 53M2 and 53M3, were gener- 
ated, replacing the AAA nucleotides in 53 by CCC; then 
they were inserted downstream of MA-00-CAT (Fig. 1). 
In F9 cells, 53Ml showed 4-fold less promoter activity 
52+53 
E39 
B 3540 
53 ~MC~;TCPCCC~A~A~A~GA~~GA~~~A~A~~~ 
3630 3717 
53 CITITCMMC~~~A~A~MC~~MG~GMGA~~ 
53M 
53u2 Pa 
53l43 rproz- 
E39 TGITCGMTGCU~~TC~TCGACTT~~T~~ATKITA 
m TCXGMTGCAAhTiXTAGAA 
Fig. 1. DNA fragments and CAT constructs used in this study. (A) A restriction map of genomic hst-1 and the DNA fragments derived from it. On 
the top, restriction sites and exon/intron organization of the human hst-1 gene are shown. Filled and open boxes represent coding and non-coding 
portions of the transcribed sequence, respectively. The restriction sites, ApaI, BsrI, BstE2, EcoRI, EcoT221, MboI, RmaI and SafI are abbreviated 
as A, B,E2, E, T,M, R and S, respectively. (B) The sequence of fragment 53 and partial sequences of mutated 53. The sequence of the 53 mutants 
are the same as that of wild-type 53, except for replacing the AAA residues by CCC. E39 is a synthetic dsDNA which contains both octamer and 
En-like sequences and OCT is a 22mer ds-oligonucleotide containing an octamer element. (C) Structure of CAT constructs. The bacterial CAT gene 
is shown as a thick black arc, and the sequences derived from SV40 and pBR322 as an unfilled arc. DNA fragments tested for promoter activity 
were inserted at the Hind111 site (H). DNA fragments tested for enhancer activity were inserted at the BamHI site after converting to an XbaI site 
00. 
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A PlasniCs Fold CAT activity 
1 MA-00-CAT 
2 &LA-OO-CAT-53 
3 IQ%-oo-CAT-53 
4 MA-OO-CAT-53M1 
5 MA-OO-CAT-53M2 
6 MA-OO-CAT-53M3 
B 
1 pSVOOCAT 
2 @VOOCAT-53 
3 -64/92-OO-CAT-53 
4 RA-OO-CAT-53 
5 BA-OO-CAT-53 
6 MA-OO-CAT-53 
Fig. 2. (A) Enhancer activity of wild-type and mutant 53. Cells were 
transfected with 20 pg of CAT constructs, 10 pug of pUC18 and 1 ,ug 
of pCHl10. F9 nuclear extracts corresponding to 30 ,oU of /I-galacto- 
sidase activity were assayed for CAT activity. One out of three experi- 
ments is shown and the results were reproducible. (B) Promoter activity 
of the 5’ region of human hst-I. Transfection protocols were the same 
as A except hat pRSV-LacZ was used in place of pCHl10. F9 nuclear 
proteins corresponding to 7.5 PLJ were assayed for CAT activity. One 
out of three experiments is shown and the results were reproducible. 
than wild-type 53, whereas the M2 mutation did not 
reduce the activity (Fig. 2A), implying that the octamer, 
but not the En-like sequence, is active as an enhancer. 
The transcription of hst-1 is repressed in F9 cells after 
differentiation [13,14]. Expression of Oct3 is also down- 
regulated after differentiation [33]. Oct3 protein is found 
only in undifferentiated embryonal carcinoma cells and 
at the early stage of embryogenesis [28,34,35]. In order 
to determine whether or not the octamer and En-like 
sequences of 53 bind Octl and/or Oct3 proteins in F9 
nuclear extract, we performed band shift assays. Probe 
53 detected Ott 1 and Oct3 proteins in F9 nuclear extract 
(Fig. 3A, lane 3) but the probe detected only Ott 1 protein 
in nuclear extracts of HeLa and NIH3T3 cells (data not 
shown). The nuclear extract of HeLa and NIH3T3 cells 
which were transiently transfected with an act-3 expres- 
sion plasmid yielded authentic Oct3 bands (see Fig. 4). 
In order to further confirm that the shifted bands actu- 
ally bound the octamer proteins, a ds synthetic 22mer 
oligonucleotide containing the ATGCAAAT core se- 
quence was used as a competitor in the band shift assay. 
The synthetic 22mer competed out both Ott-1 and Ott-3 
proteins in F9 cells (Fig. 3A, lane 2). The mutant 53 
probes were also tested by band shift assay. Wild-type 53 
and 53M2 probes detected Octl and Oct3 proteins in F9 
cells (Fig. 3A, lanes 3 and 5), but 53Ml and 53M3 probes 
detected only small amounts, if any, of Octl and Oct3 
proteins (lanes 4 and 6). In competitive band shift assays, 
wild-type 53 ad 53M2 almost completely competed out 
the binding of labeled E39 probe to Octl and Oct3 pro- 
teins of F9 nuclear extracts (Fig. 3B, lanes 2 and 4). 
In order to define the promoter region of the hst-1 
73 
gene, 5’ fragments horter than MA were tested for pro- 
moter activity. Two DNA fragments, -172/105 (RA) 
and -2&Z/105 (BA) had promoter activity substantially 
higher than MA, whereas -64/92 retained weak activity 
when these fragments were inserted upstream of the CAT 
gene of pSVOOCAT-53 (Fig. 2B). Ma et al. [21] observed 
positive regulatory activity between -267/-61 of the 
mouse hst-1 5’ sequence which corresponds to -2981-65 
of the human counterpart. In this study, we narrowed the 
promoter-active region to - 172/-65. 
To test whether or not Oct3 directly enhances the hst-1 
promoter, a CMV-driven act3 expression plasmid [28] 
was co-transfected into HeLa, PYS-2 and NIH3T3 cells 
with various CAT constructs. The act-3 expression plas- 
mid was sequenced again before this experiment and its 
authenticity was verified. The transfected act-3 plasmid 
was expressed, at least in HeLa and NIH3T3 cells, as 
judged by the mobility shift experiment (Fig. 4, lanes 2, 
4, 6, 14, 16 and 18). Such shifts which appeared below 
o&3 of act-Etransfected HeLa cells (lanes 2, 4 and 6) 
were not demonstrable when the 22mer octamer probe 
was used instead of E39. However, in PYS-2, nuclear 
extracts which had been co-transfected with the act-3 
expression plasmid showed very weak Oct3 signals 
competitor 
pUC18 
act 
competitor 
53 
53Ml 
53M2 
53M3 
pUC18 
probe 
53 
53 
53 
53Ml 
53M2 
53M3 
probe 
E39 
E39 
E39 
E39 
E39 
E39 
Fig. 3. (A) Band shift of wild-type and mutant 53 probes by undifferen- 
tiated F9 nuclear extract. The following probes were used: wild-type 53 
(lanes l-3); 53Ml (lane 4); 53M2 (lane 5); 53M3 (lane 6). Competitors 
were a 200-fold molar excess 22mer oligonucleotide containing only the 
octamer sequence (lane 2) or 10 ng of pUC18 (lane 1). (B) Competition 
of band shifts by wild-type and mutant 53. Band shifts were performed 
using F9 nuclear extract and labeled E39 oligonucleotide, in which a 
200 molar excess of competitors were included. The competitors used 
were: no competitor (lane 1); wild-type 53 (lane 2); 53Ml (lane 3); 53M2 
(lane 4); 53M3 (lane 5); and 260 ng pUC18 (lane 6). 
00-m 
0%cm/ o&-l 
u-00-~ 
Ra-I Oct.4 
U-w-~-53 
UI-oc-CAT-ll,oct-3 
oo-cm 
OO-CXf, wt.4 
XbOO-C&Z 
u-CQ-cmI act-3 
RA-oo-cA!r-53 
R&4O-CXC-53,OOt-3 
oo-CAT 
w-w/ act-3 
RI-M-CAT 
M-00-C&T, Oct.4 
RA-ccl-cm-53 
Rh-OO-CAT-53/O&-3 
Fig. 4. Transient expression of Oct3 did not enhance hst-I promoter 
activity in HeLa, PYS-2 and NIH3T3 cells. Transfected calcium precip- 
itates contained 20 pug CAT constructs, 3 ,ug CMV-act-3 and 1 ,ug 
pRSV-LacZ. Lanes 16, HeLa cells; lanes 7-12, PYS-2 cells; and lanes 
13-18, NIH3T3 cells. Transfected plasmids were as follows:OO-CAT 
(lanes 1, 7 and 13); 00-CAT plus act-3 (lanes 2, 8 and 14); RA-OO- 
CAT (lanes 3, 9 and 15); RA-00-CAT plus act-3 (lanes 4, 10 and 16); 
RA-00-CAT-53 (lanes 5, 11 and 17); RA-00-CAT-53 plus act-3 (lanes 
6,12 and 18). CAT activities represent the gross percentage of chloram- 
phenicol acetylation for 3 h at 30°C. j?-Galactosidase activity was 
expressed as ,& per ~1 nuclear extract. For the band shift assay, E39 
was used as the probe. One out of three experiments is shown. The 
results of other experiments were comparable to those shown here. 
(Fig. 4, lanes 8, 10 and 12). CAT activity in these exper- 
iments were not corrected for /3-galactosidase activity of 
co- transfected pRSV-LacZ, since transfection of act-3 
expression plasmid reduced /?-galactosidase activity of 
PYS-2 cells consistently (Fig. 4, lanes 8, 10 and 12). The 
results of Fig. 4 clearly demonstrated that Oct3 did not 
enhance the reporter RA-00-CAT-53. We also co-trans- 
fected the CMV-driven act3 expression plasmid with 
reporter genes into F9 cells undergoing differentiation, 
but no enhancement of RA-00-CAT-53 and BA-OO- 
CAT-53 was observed (data not shown). In PYS-2 cells 
RA-00-CAT showed higher p omoter activity than RA- 
00-CAT-53 (Fig. 4, compare lanes 9 and 11) and the 
activities were reduced by co-transfection with the act-3 
expression plasmid. The reason for this finding 
clear at present, but is repeatedly observed. 
is not 
4. Discussion 
Previous reports have suggested that the enhancer ac- 
tivity of the octamer motif is present at the 3’ end of 
human [19,20,22] and mouse [20,21] hst-1 genes. Among 
these investigations the most thorough was that of 
Schoorlemmer and Kruijer [22], which demonstrated 
that the deletion of the candidate octamer sequence re- 
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sulted in the loss of enhancer activity. In this investiga- 
tion, we confirmed their finding and demonstrated that 
the octamer sequence present at 3,655, but not the En- 
like sequence present near-by had enhancer activity. 
Tissue specific gene activation through two octamer 
binding proteins, Pit1 and Octl, have been analyzed in 
detail [36]. In the immunoglobulin heavy chain gene, two 
octamer sequences are present both 3’ and 5’ to the cod- 
ing region [37,38]. The hst-1 gene may be unique in that 
the tissue specific transcription is enhanced by the oc- 
tamer sequence present only 3’ to the coding region. The 
location of the octamer sequence 3’ to the coding region 
is not unique to hst-Z, but is rather common to the genes 
for members of the FGF family such as KGI;117] and 
basic FGF [38]. The role of these octamer motifs has not 
been analyzed as yet. 
As Oct3 expression is down-regulated along with hst-Z 
when F9 cells differentiate to parietal endoderm-like 
cells, it is conceivable that Oct3 activates the ha-l pro- 
moter. In fact, Ma et al. reported that transfection of a 
CMV-driven act3 expression plasmid into differentiated 
F9 cells and PYS-2, a cell line having characteristics 
similar to differentiated F9, resulted in the activation of 
the murine hst-1 promoter [21]. However, in this study, 
transient expression of Oct3 did not enhance transcrip- 
tion of an hst-I-CAT-octamer reporter gene in either 
PYS-2, HeLa or NIH3T3 cells (Fig. 4). We also failed to 
demonstrate the enhancement of the same reporter gene 
by co-transfection of the act-3 expression plasmid into 
differentiated F9 cells (data not shown). In these experi- 
ments, the CAT activities were not corrected for /I-galac- 
tosidase activity, since expression of Oct3 protein down- 
regulated the promoter activity [39,40]. In the present 
study, when the act3 expression plasmid was introduced 
into PYS-2 cells, /I-galactosidase activities were reduced 
dramatically (Fig. 4). Such a difference between octS- 
transfected and untransfected PYS-2 cells might not be 
ascribed to difference in transfection efficiencies. There- 
fore, we are afraid that correction of the CAT activity by 
transfection efficiency using the p-galactosidase activities 
of co-transfected pCHll0 or pRSV-LacZ may be mis- 
leading in these experiments. 
The reason for the lack of activation of hst-Z promoter 
by Oct3 may be the absence of a transcription factor in 
differentiated cells such as HeLa, PYS-2 and NIH3T3 
cells. Alternatively, a transcriptional repressor may be 
absent in undifferentiated F9 cells, thus allowing the 
octamer binding factor to interact with the promoter 
factors. Such a mechanism has been reported for the 
transcriptional repression of HIV by the protein factor, 
LBP-1 [41]. We are currently analyzing the protein fac- 
tors which bind to the promoter region of hst-Z. 
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